Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
Cholangiocarcinoma Metastatic
DRUG: TT-00420 (tinengotinib)
Objective Response Rate (ORR) by BICR, The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1., Through study completion, an average of 1 year
Progression-free survival (PFS), From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, Through study completion, an average of 1 year|Overall Survival (OS), From first study drug administration until the date of death from any cause, Through study completion, an average of 1 year|ORR by Investigator, The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1., Through study completion, an average of 1 year|Disease control rate (DCR), The proportion of subjects who achieved a complete response (CR) or a partial response (PR) or a stable disease (SD) based on RECIST version 1.1., Through study completion, an average of 1 year|Duration of response (DOR), Duration of response for CR or PR based on RECIST version 1.1., Through study completion, an average of 1 year|Incidence, duration, and severity of adverse events (AEs), As assessed per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (or the most current version)., Up to 28 days from study discontinuation
Approximately 50 subjects will be enrolled. Eligible subjects will receive tinengotinib 10 mg QD orally as the initial dose level in 21-day cycles until confirmed disease progression, intolerable toxicity, death, or withdrawal of consent.